AZN catalysts

Catalysts and events linked to AZN, newest first.

DateCardAvg 5d

2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN
2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOAZN HCM+4.82%
2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026AZN HCM+4.82%
2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressAZN HCM+4.82%
2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026AZN HCM+4.82%
2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOAZN HCM+4.82%
2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressAZN HCM+4.82%
2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOAZN HCM+4.82%
2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026AZN HCM+4.82%
2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOAZN HCM+4.82%
2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026AZN HCM+4.82%
2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksAZN IONS+1.49%
2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsAZN IONS+1.49%
2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksAZN BIIB IONS+1.49%
2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksAZN IONS+1.49%
2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenAZN BIIB IONS+1.49%
2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial dataAZN
2026-08-31HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLCAZN
2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial dataAZN HCM+14.52%
2026-08-31HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLCAZN HCM+14.52%
2026-08-31HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLCAZN HCM+14.52%
2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial dataAZN HCM+14.52%
2026-08-31HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus TagrissoAZN HCM+14.52%
2026-08-31HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in ChinaAZN HCM+14.52%
2026-06-15AstraZeneca Wins FDA Approval for Targeted Prostate Cancer TreatmentAZN

See today's live cards

Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

Open Desk — $399/month